Skip to main content
SpringerLink
Log in

Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries

  • Chapter
  • First Online:
Book cover Diabetes Mellitus in Developing Countries and Underserved Communities

Abstract

The global prevalence of diabetes currently exceeds 400 million and is projected to increase to more than 600 million affected persons by the year 2035. Developing countries will account for the greater proportion of the projected increase in diabetes prevalence. Indeed, if current trends remain unabated, people with diabetes in developing countries will comprise >70 % of the global diabetes burden by the year 2035. Diabetes is now the leading cause of blindness, end-stage renal failure, nontraumatic limb amputations, heart disease, and stroke. These expensive complications inflict a major drain on the economies of even upper-income countries; indeed, most developing countries lack the resources for tackling the challenges of diabetes care delivery and effective management of its complications. There is now abundant evidence that type 2 diabetes (which accounts for greater than 90 % of diabetes worldwide) can be prevented: the challenge is how best to translate the results of clinical trials globally to communities with disparate resources and capabilities. This chapter makes the compelling case for primary prevention of diabetes as an imperative for developing countries and discusses how that can be accomplished, including the novel concept Community Diabetes Prevention Centers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. International Diabetes Federation. IDF diabetes atlas 2015. 7th ed. Brussels: International Diabetes Federation; 2015.

    Google Scholar 

  2. Geiss LS, Wang J, Cheng YJ, Thompson TJ, Barker L, Li Y, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980–2012. JAMA. 2014;312:1218–26.

    Article  CAS  PubMed  Google Scholar 

  3. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514–23.

    Article  CAS  PubMed  Google Scholar 

  4. World Health Organization. Global status report on noncommunicable diseases 2014. Geneva: WHO Press; 2014.

    Google Scholar 

  5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

    Article  CAS  PubMed  Google Scholar 

  6. Hu F. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011;34:1249–57.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Egede LE, Dagogo-Jack S. Epidemiology of type 2 diabetes: focus on ethnic minorities. Med Clin N Am. 2005;89:949–75.

    Article  PubMed  Google Scholar 

  8. Tanizawa Y, Riggs AC, Dagogo-Jack S, Vaxillaire M, Froguel P, Liu L, et al. Isolation of the human LIM/homeodomain gene islet-1 and identification of a simple sequence repeat polymorphism. Diabetes. 2004;43:935–41.

    Article  Google Scholar 

  9. Ehm MG, Karnoub MC, Sakul H, Gottschalk K, Holt DC, Weber JL, American Diabetes Association GENNID Study Group. Genetics of NIDDM, et al. Genome wide search for type 2 diabetes susceptibility genes in four American populations. Am J Hum Genet. 2000;66:1871–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. McCarthy M, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep. 2009;9:164–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, et al. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011;60:1340–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Dagogo-Jack S. Predicting diabetes: our relentless quest for genomic nuggets. Diabetes Care. 2012;35:193–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016;39:S1–112.

    Article  Google Scholar 

  14. Fujimoto WY, Leonetti DL, Kinyoun JL, Newell-Morris L, Shuman WP, Stolov WC, et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes. 1987;36:721–9.

    Article  CAS  PubMed  Google Scholar 

  15. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med. 1997;157:1802–17.

    Article  CAS  PubMed  Google Scholar 

  16. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Rasmussen BB, Holmbäck UC, Volpi E, Morio-Liondore B, Paddon-Jones D, Wolfe RR. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1 activity and fat oxidation in human skeletal muscle. J Clin Invest. 2002;110:1687–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404–14.

    Article  PubMed  Google Scholar 

  20. Larson-Meyer DE, Heilbronn LK, Redman LM, Newcomer BR, Frisard MI, Anton S, et al. Effect of calorie restriction with or without exercise on insulin sensitivity, β-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care. 2006;29:1337–44.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Rev. 1995;3:366–77.

    Google Scholar 

  22. Schneider SH, Morgado A. Effects of fitness and physical training on carbohydrate metabolism and associated cardiovascular risk factors in patients with diabetes. Diabetes Rev. 1995;3:378–407.

    Google Scholar 

  23. Rogers MA, Yamamoto C, King DS, Harberg JM, Ensani AA, Holloszy JO. Improvement in glucose tolerance after one week of exercise in patients with mild NIDDM. Diabetes Care. 1988;11:613–8.

    Article  CAS  PubMed  Google Scholar 

  24. Eriksson KF, Lindgarde F. Prevention of type 2 diabetes mellitus by diet and physical exercise. Diabetologia. 1991;34:891–8.

    Article  CAS  PubMed  Google Scholar 

  25. Mikines KJ, Sonne B, Farrell PA, Tronier B, Galbo H. Effect of physical exercise on sensitivity and responsiveness to insulin in humans. Am J Physiol. 1988;254:E248–59.

    CAS  PubMed  Google Scholar 

  26. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med. 1998;49:235–61.

    Article  CAS  PubMed  Google Scholar 

  27. Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, et al. Very-low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiologic changes in responders and nonresponders. Diabetes Care. 2016. pii: dc151942. [Epub ahead of print].

    Google Scholar 

  28. Dagogo-Jack S, Edeoga C. Understanding and identifying pre-diabetes – can we halt the diabetes epidemic? Eur Endocrinol. 2008;4:16–8.

    Article  Google Scholar 

  29. Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target. Clin Chem. 2011;57:215–20.

    Article  CAS  PubMed  Google Scholar 

  30. Maschirow L, Khalaf K, Al-Aubaidy HA, Jelinek HF. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes — biomarkers as a possible tool for early disease detection for rural screening. Clin Biochem. 2015;48:581–5.

    Article  CAS  PubMed  Google Scholar 

  31. Nyenwe EA, Dagogo-Jack S. Metabolic syndrome, prediabetes and the science of primary prevention. Minerva Endocrinol. 2011;36:129–45.

    CAS  PubMed  Google Scholar 

  32. Tabák A, Herder C, Rathmann W, Brunner E, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279–90.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Weir G, Bonner-Weir S. Five stages of evolving progression to diabetes. Diabetes. 2004;53:S16–21.

    Article  CAS  PubMed  Google Scholar 

  34. Weyer C, Bogardus C, Mott DM, Pratley R. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86:3717–23.

    Article  CAS  PubMed  Google Scholar 

  36. Papaetis G. Incretin-based therapies in prediabetes: current evidence and future perspectives. World J Diabetes. 2014;5:817–34.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lopategi A, López-Vicario C, Alcaraz-Quiles J, García-Alonso V, Titos E, Clària J, et al. Role of bioactive lipid mediators in obese adipose tissue inflammation and endocrine dysfunction. Mol Cell Endocrinol. 2016;419:44–59.

    Article  CAS  PubMed  Google Scholar 

  38. Cerasi E, Luft R. The prediabetic state, its nature and consequences – a look toward the future. Diabetes. 1972;21 Suppl 2:685–94.

    Article  CAS  PubMed  Google Scholar 

  39. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014. Atlanta: US Department of Health and Human Services; 2014.

    Google Scholar 

  40. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46:701–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol. 1978;108:497–505.

    CAS  PubMed  Google Scholar 

  42. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000;283:2253–9.

    Article  CAS  PubMed  Google Scholar 

  43. Weyer C, Tataranni PA, Bogardus C, Pratley R. Diabetes Care. 2000;24:89–94.

    Article  Google Scholar 

  44. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. Diabetes. 2003;52:1475–84.

    Article  CAS  PubMed  Google Scholar 

  45. Dagogo-Jack S, Edeoga C, Ebenibo S, Nyenwe E, Wan J. Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. J Clin Endocrinol Metab. 2014;99:E1078–87.

    Article  CAS  PubMed  Google Scholar 

  46. Boucher AB, Adesanya EAO, Owei I, Gilles AK, Ebenibo S, Wan J, Edeoga C, Dagogo-Jack S. Dietary habits and leisure-time physical activity in relation to adiposity, dyslipidemia, and incident dysglycemia in the Pathobiology of Prediabetes in A Biracial Cohort Study. Metabolism. 2015;64:1060–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Jiang Y, Owei I, Wan J, Ebenibo S, Dagogo-Jack S. Adiponectin levels predict prediabetes risk: the pathobiology of prediabetes in a biracial cohort (POP-ABC) study. BMJ Open Diabetes Res Care. 2016;4:e000194. doi:10.1136/bmjdrc-2016.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.

    Article  CAS  PubMed  Google Scholar 

  49. Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.

    Article  CAS  PubMed  Google Scholar 

  50. DPP Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  Google Scholar 

  51. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.

    Article  CAS  PubMed  Google Scholar 

  52. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.

    Article  PubMed Central  Google Scholar 

  53. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293–301.

    Article  PubMed  Google Scholar 

  54. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81:19–27.

    PubMed  PubMed Central  Google Scholar 

  55. Deeb LC, Tan MH, Alberti KGMM. Insulin availability among International Diabetes Federation member associations. Diabetes Care. 1994;17:220–3.

    Article  CAS  PubMed  Google Scholar 

  56. Dagogo-Jack S. DCCT results and diabetes care in developing countries. Diabetes Care. 1995;18:416–7.

    Article  CAS  PubMed  Google Scholar 

  57. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. Lancet. 2006;368:1689–95.

    Article  PubMed  Google Scholar 

  58. Dagogo-Jack S. Pattern of foot ulcer in diabetic Nigerians. Pract Diabetes Dig. 1991;2:75–8.

    Google Scholar 

  59. Dagogo-Jack S. Diabetic in-patient mortality in Nigeria. Pract Diabetes Dig. 1991;2:117–9.

    Google Scholar 

  60. Dagogo-Jack S. Primary prevention of cardiovascular disease in diabetic patients. Cardiol Q. 2006;12:20–5.

    Google Scholar 

  61. Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, DCCT/EDIC Research Group, et al. Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62:3976–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

    Article  Google Scholar 

  63. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Duckworth, VADT Investigators, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–206.

    Article  CAS  PubMed  Google Scholar 

  64. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.

    Article  CAS  PubMed  Google Scholar 

  65. Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143–53.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999–2010. New Engl J Med. 2013;368:1613–24.

    Article  CAS  PubMed  Google Scholar 

  67. Dagogo-Jack S. Preventing diabetes-related morbidity and mortality in the primary care setting. J Natl Med Assoc. 2002;94:549–60.

    PubMed  PubMed Central  Google Scholar 

  68. Dagogo-Jack S. Primary prevention of type 2 diabetes in developing countries. J Natl Med Assoc. 2006;98:415–9.

    PubMed  PubMed Central  Google Scholar 

  69. Echouffo-Tcheugui JB, Dagogo-Jack S. Preventing diabetes mellitus in developing countries. Nat Rev Endocrinol. 2012;8:557–62.

    Article  PubMed  Google Scholar 

  70. Dabelea D, Knowler WC, Pettitt DJ. Effect of diabetes in pregnancy on offspring: follow-up research in the Pima Indians. J Matern Fetal Med. 2000;9:83–8.

    CAS  PubMed  Google Scholar 

  71. Francis-Emmanuel PM, Thompson DS, Barnett AT, Osmond C, Byrne CD, Hanson MA, et al. Glucose metabolism in adult survivors of severe acute malnutrition. J Clin Endocrinol Metab. 2014;99:2233–40.

    Article  CAS  PubMed  Google Scholar 

  72. Dagogo-Jack S. HIV therapy and diabetes risk (Editorial). Diabetes Care. 2008;31:1267–8.

    Article  PubMed  Google Scholar 

  73. Yarasheski K, Tebas P, Sigmund CM, Dagogo-Jack S, Bohrer A, Turk J, Cryer PE, Powderly WG. Insulin resistance in HIV-protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr. 1999;21:209–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379:2243–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Article  PubMed Central  Google Scholar 

  76. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–9.

    Article  PubMed  Google Scholar 

  77. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–80.

    Article  PubMed  Google Scholar 

  78. Simmons D, Rush E, Crook N. Development and piloting of a community health worker-based intervention for the prevention of diabetes among New Zealand Maori in Te Wai o Rona: diabetes prevention strategy. Public Health Nutr. 2008;11:1318–25.

    Article  CAS  PubMed  Google Scholar 

  79. Ackermann RT, Marrero DG. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ. 2007;33(69):74–5, 77–8.

    Google Scholar 

  80. Albright AL, Gregg EW. Preventing type 2 diabetes in communities across the U.S.: the National Diabetes Prevention Program. Am J Prev Med. 2013;44(4 Suppl 4):S346–51.

    Article  PubMed  PubMed Central  Google Scholar 

  81. Albright A. The National Diabetes Prevention Program: from research to reality. Diabetes Care Educ Newsl. 2012;33(4):4–7.

    PubMed  PubMed Central  Google Scholar 

  82. Hays LM, Finch EA, Saha C, Marrero DG, Ackermann RT. Effect of self-efficacy on weight loss: a psychosocial analysis of a community-based adaptation of the diabetes prevention program lifestyle intervention. Diabetes Spectr. 2014;27:270–5.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Velicer WF, Brick LA, Fava JL, Prochaska JO. Testing 40 predictions from the transtheoretical model again. With confidence. Multivar Behav Res. 2013;48:220–40.

    Article  Google Scholar 

  84. Norcross JC, Krebs PM, Prochaska JO. Stages of change. J Clin Psychol. 2011;67:143–54.

    Article  PubMed  Google Scholar 

  85. Pan WH, Flegal KM, Chang HY, Yeh WT, Yeh CJ, Lee WC. Body mass index and obesity-related metabolic disorders in Taiwanese and US whites and blacks: implications for definitions of overweight and obesity for Asians. Am J Clin Nutr. 2004;79:31–9.

    CAS  PubMed  Google Scholar 

  86. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090–101.

    Article  CAS  PubMed  Google Scholar 

  87. Pohl JH, Greer JA, Hasan KS. Type 2 diabetes mellitus in children. Endocr Pract. 1998;4:413–6.

    Article  CAS  PubMed  Google Scholar 

  88. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002;15 Suppl 2:737–44.

    PubMed  Google Scholar 

  89. Alberti G, Zimmet P, Shaw J, Bloomgarden Z, Kaufman F, Silink M, Consensus Workshop Group. Type 2 diabetes in the young: the evolving epidemic: the international diabetes federation consensus workshop. Diabetes Care. 2004;27:1798–811.

    Article  PubMed  Google Scholar 

  90. Wiegand S, Maikowski U, Blankenstein O, Biebermann H, Tarnow P, Gruters A. Type 2 diabetes and impaired glucose tolerance in European children and adolescents with obesity - a problem that is no longer restricted to minority groups. Eur J Endocrinol. 2004;151:199–20.

    Article  CAS  PubMed  Google Scholar 

  91. Caprio S. Development of type 2 diabetes mellitus in the obese adolescent: a growing challenge. Endocr Pract. 2012;18:791–5.

    Article  PubMed  Google Scholar 

  92. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013;36:1735–41.

    Article  PubMed Central  CAS  Google Scholar 

  93. HEALTHY Study Group. A school-based intervention for diabetes risk reduction. N Engl J Med. 2010;363:443–5.

    Article  Google Scholar 

  94. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25:2165–71.

    Article  Google Scholar 

  95. Eriksson KF, Lindgarde F. Prevention of type 2 (noninsulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia. 1991;4:891–8.

    Article  Google Scholar 

  96. Pate RR, Pratt M, Blair SN, Haskell WL, Macera CA, Bouchard C, et al. Physical activity and public health: recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA. 1995;273:402–7.

    Article  CAS  PubMed  Google Scholar 

  97. Kimm SY, Glynn NW, Kriska AM, Barton BA, Kronsberg SS, Daniels SR, et al. Decline in physical activity in black and white girls during adolescence. N Engl J Med. 2002;347:709–15.

    Article  PubMed  Google Scholar 

  98. Hood MS, Little JP, Tarnopolsky MA, Myslik F, Gibala MJ. Low-volume interval training improves muscle oxidative capacity in sedentary adults. Med Sci Sports Exerc. 2011;43:1849–56.

    Article  CAS  PubMed  Google Scholar 

  99. Tate DF, Wing RR, Winett RA. Using Internet technology to deliver a behavioral weight loss program. JAMA. 2001;285:1172–7.

    Article  CAS  PubMed  Google Scholar 

  100. Neve M, Morgan PJ, Jones PR, Collins CE. Effectiveness of web-based interventions in achieving weight loss and weight loss maintenance in overweight and obese adults: a systematic review with meta-analysis. Obes Rev. 2010;11:306–21.

    Article  CAS  PubMed  Google Scholar 

  101. Kodama S, Saito K, Tanaka S, Horikawa C, Fujiwara K, Hirasawa R, et al. Effect of Web-based lifestyle modification on weight control: a meta-analysis. Int J Obes (Lond). 2012;36:675–85.

    Article  CAS  Google Scholar 

  102. Kohl LF, Crutzen R, de Vries NK. Online prevention aimed at lifestyle behaviors: a systematic review of reviews. J Med Internet Res. 2013;15:e146. doi:10.2196/jmir.2665.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Watson S, Woodside JV, Ware LJ, Hunter SJ, McGrath A, Cardwell CR, et al. Effect of a web-based behavior change program on weight loss and cardiovascular risk factors in overweight and obese adults at high risk of developing cardiovascular disease: randomized controlled trial. J Med Internet Res. 2015;17(7):e177. doi:10.2196/jmir.3828.

    Article  PubMed  PubMed Central  Google Scholar 

  104. US Department of Agriculture Center for Nutrition Policy and Promotion. Dietary guidelines for Americans. http://www.cnpp.usda.gov/dietaryguidelines.htm. Accessed 5 Apr 2016.

  105. Camelon KM, Hådell K, Jämsén PT, Ketonen KJ, Kohtamäki HM, Mäkimatilla S, et al. The Plate Model: a visual method of teaching meal planning. DAIS Project Group. Diabetes Atherosclerosis Intervention Study. J Am Diet Assoc. 1998;98:1155–8.

    Article  CAS  PubMed  Google Scholar 

  106. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(Suppl):222S–5.

    CAS  PubMed  Google Scholar 

  107. Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J, Diabetes Prevention Program Research Group. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7.

    Article  PubMed  PubMed Central  Google Scholar 

  108. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.

    Article  CAS  PubMed  Google Scholar 

  109. Orgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.

    Article  Google Scholar 

  110. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.

    Article  CAS  Google Scholar 

  111. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, ACT NOW Study, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15 (Erratum in: N Engl J Med. 2011;365:189).

    Article  CAS  PubMed  Google Scholar 

  112. Zinman B, Harris SB, Neuman J, Gerstein HC, Retnakaran RR, Raboud J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet. 2010;376:103–11.

    Article  CAS  PubMed  Google Scholar 

  113. NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477–90 (Erratum in: N Engl J Med. 2010;362:1748).

    Article  Google Scholar 

  114. DPP Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care. 2003;26:977–80.

    Article  Google Scholar 

  115. DREAM Trial Investigators. Incidence of diabetes following ramipril or rosiglitazone withdrawal. Diabetes Care. 2011;34:1265–9.

    Article  CAS  Google Scholar 

  116. Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, et al. Diabetes incidence and glucose tolerance after termination of pioglitazone therapy: results from ACT NOW. J Clin Endocrinol Metab. 2016:jc20154202. [Epub ahead of print].

    Google Scholar 

  117. Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CK, Seeli AC, Shetty AS. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia. 2009;52:1019–26.

    Article  CAS  PubMed  Google Scholar 

  118. Greenway FL. Physiological adaptations to weight loss and factors favouring weight regain. Int J Obes (Lond). 2015. doi:10.1038/ijo.2015.59.

    Google Scholar 

  119. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired fasting glucose and impaired glucose tolerance. Diabetes Care. 2007;30:753–9.

    Article  CAS  PubMed  Google Scholar 

  120. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR. Australian Diabetes Society and Australian Diabetes Educators Association. Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust. 2007;186:461–5.

    PubMed  Google Scholar 

  121. Indian Health Services. 2008 IHS guidelines for care of adults with prediabetes and/or the metabolic syndrome in clinical settings. http://aianp.ucdenver.edu/sdpi/common/initiative/DP_Appendices/DPIAN6%20IHS%20Guidelines%20PreDiabetes%20Metsyn%20Sept%202008.pdf. Accessed 3 Apr 2016.

  122. Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab. 2009;94:2031–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Kanat M, Mari A, Norton L, Winnier D, DeFronzo RA, Jenkinson C, Abdul-Ghani MA. Distinct β-cell defects in impaired fasting glucose and impaired glucose tolerance. Diabetes. 2012;61:447–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS, Narayan KM, et al. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care. 2010;33:49–54.

    Article  CAS  PubMed  Google Scholar 

  125. Diabetes Prevention Program (DPP) Research Group. Cost associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program. Diabetes Care. 2003;26:36–47.

    Article  Google Scholar 

  126. Diabetes Prevention Program Research Group. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care. 2003;26:2518–23.

    Article  Google Scholar 

  127. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Diabetes Prevention Program Research Group, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005;142:323–32.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care. 2012;35:723–30.

    Article  CAS  Google Scholar 

  129. Ramachandran A, Snehalatha C, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians: within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care. 2007;30:2548–52.

    Article  PubMed  Google Scholar 

  130. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care. 2006;29:1237–41.

    Article  PubMed  Google Scholar 

  131. Dagogo-Jack S. 2015 Presidential address: 75 years of battling diabetes-our global challenge. Diabetes Care. 2016;39:3–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

SD-J is supported, in part, by grants (R01 DK067269, DK62203, DK48411) from the National Institutes of Health.

Disclosures

The author has no conflicts of interest with regard to the content of this chapter.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes & Metabolism, University of Tennessee Health Science Center, 920 Madison Avenue, Memphis, TN, 38163, USA

    Sam Dagogo-Jack MD, MBBS, MSc, FRCP, FACP, FACE

Authors
  1. Sam Dagogo-Jack MD, MBBS, MSc, FRCP, FACP, FACE
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sam Dagogo-Jack MD, MBBS, MSc, FRCP, FACP, FACE .

Editor information

Editors and Affiliations

  1. University of Tennessee Health Science Center, Memphis, Tennessee, USA

    Sam Dagogo-Jack

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dagogo-Jack, S. (2017). Primary Prevention of Type 2 Diabetes: An Imperative for Developing Countries. In: Dagogo-Jack, S. (eds) Diabetes Mellitus in Developing Countries and Underserved Communities. Springer, Cham. https://doi.org/10.1007/978-3-319-41559-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41559-8_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41557-4

  • Online ISBN: 978-3-319-41559-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation